The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer.
Y. Kikuchi
No relevant relationships to disclose
M. Takano
No relevant relationships to disclose
T. Goto
No relevant relationships to disclose
H. Kouta
No relevant relationships to disclose
R. Kikuchi
No relevant relationships to disclose
K. Kudoh
No relevant relationships to disclose
T. Kita
No relevant relationships to disclose
K. Furuya
No relevant relationships to disclose
K. Umayahara
No relevant relationships to disclose
K. Takizawa
No relevant relationships to disclose